Given WB-MRI's high sensitivity, it has been recommended for patients affected by bone solitary plasmocitoma and for patients suspected of having non-IgM monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma or multiple myeloma and who underwent low-dose WB-CT or (FDG)PET/CT with negative or inconclusive findings [11, 12]. This evidence concerns the gene CD40LG and plasma cell myeloma.